Plant Name: Salvia oxyodon
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.430E-13 | 1.182E-08 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.111E-12 | 3.387E-08 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.789E-11 | 9.739E-08 | CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.899E-09 | 1.052E-05 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.341E-09 | 1.454E-05 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 8.926E-09 | 1.944E-05 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.193E-08 | 3.979E-05 | CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 6.769E-08 | 1.053E-04 | CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 7.853E-08 | 1.069E-04 | CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.322E-07 | 1.589E-04 | CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 2.351E-07 | 2.226E-04 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 7.235E-07 | 6.059E-04 | CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.447E-06 | 1.086E-03 | CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0044281; small molecule metabolic process | 4.119E-06 | 2.718E-03 | CA12, CA9, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 5.059E-06 | 3.060E-03 | CYP2A6, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.083E-05 | 5.896E-03 | CYP2C19, CYP2C9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 1.048E-10 | 7.444E-09 | CYP2C9; CYP2A6; CYP2D6; CYP3A4; CYP2C19 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 3.373E-08 | 1.197E-06 | CYP2C9; CYP2A6; CYP2D6; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 5.409E-08 | 1.280E-06 | CYP2C9; CYP2A6; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 3.267E-07 | 5.798E-06 | CYP2C9; CYP3A4; CYP2C19 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.868E-06 | 5.493E-05 | CYP2C9; CYP2A6; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.994E-05 | 2.359E-04 | CYP2C9; CYP2D6; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 4.187E-04 | 3.303E-03 | CYP2C9; CYP2C19 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.302E-04 | 2.043E-03 | CYP2A6; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.276E-03 | 1.612E-02 | CYP2C9; CYP2A6; CYP2C19; CYP3A4 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 4.206E-03 | 2.489E-02 | NFKB1; TSHR |
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.048E-05 | 3.091E-04 | CA12; CA9 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.498E-03 | 1.612E-02 | CYP2A6 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; ACHE; ACHE |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
| NA: NA | Upper abdominal bloating | NA | ACHE |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA9; NFKB1; ACHE |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE |